Viewing Study NCT03175705



Ignite Creation Date: 2024-05-06 @ 10:08 AM
Last Modification Date: 2024-10-26 @ 12:25 PM
Study NCT ID: NCT03175705
Status: UNKNOWN
Last Update Posted: 2018-01-18
First Post: 2017-05-24

Brief Title: Adoptive Transfer of Specific HCC Antigens CD8 T Cells for Treating Patients With RelapsedAdvanced HCC
Sponsor: Beijing YouAn Hospital
Organization: Beijing YouAn Hospital

Study Overview

Official Title: A Study of Specific HCC Antigens CD8 T Cells Therapy for Treating Patients With RelapsedAdvanced Hepatocellular Carcinoma HCC
Status: UNKNOWN
Status Verified Date: 2018-01
Last Known Status: RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This study enrolls patients who have relapsedadvanced hepatocellular carcinoma HCC BCLC stage C The HCC tumor relapsed or metastasized through the body after standard treatment or the patients cannot receive standard treatment under current conditions This research study uses specific HCC antigens CD8 T cells a new experimental treatment

The purpose of this study is to evaluate the safety and tolerance as well as the potential clinical efficacy of an adoptive transfer of CD8 T cells sorted with human leukocyte antigen HLA-peptide multimers and specific for Glypican GPC-3 New York Esophageal Squamous-1 NY-ESO-1 alpha-fetoprotein AFP antigens and cultured in vitro to patients suffering from relapsedadvanced hepatocellular carcinoma HCC
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None